Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000803381 | SCV000943248 | uncertain significance | Joubert syndrome 20; Meckel syndrome, type 11 | 2023-11-06 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with glutamine, which is neutral and polar, at codon 112 of the TMEM231 protein (p.Pro112Gln). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with clinical features of Joubert syndrome and related disorders (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 648618). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002537159 | SCV003730306 | uncertain significance | Inborn genetic diseases | 2022-02-11 | criteria provided, single submitter | clinical testing | The c.263C>A (p.P88Q) alteration is located in exon 1 (coding exon 1) of the TMEM231 gene. This alteration results from a C to A substitution at nucleotide position 263, causing the proline (P) at amino acid position 88 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |